Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implications for neuroprotective treatments.

Brian S Meldrum1

  • 1GKT School of Biomedical Sciences, Henriette Raphael House, Guy's Campus, London SE1 1UL, UK. brian.meldrum@kcl.ac.uk

Progress in Brain Research
|July 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetically epilepsy-prone rats (GEPRs) and DBA/2 mice: Two animal models of audiogenic reflex epilepsy for the evaluation of new generation AEDs.

Epilepsy & behavior : E&B·2015
Same author

Molecular targets for antiepileptic drug development.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2007
Same author

Glutamate metabotropic receptors as targets for drug therapy in epilepsy.

European journal of pharmacology·2003
Same author

The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings.

Journal of neurochemistry·2003
Same author

Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure.

Epilepsia·2002
Same author

Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity.

Farmaco (Societa chimica italiana : 1989)·2002
Same journal

Preface.

Progress in brain research·2025
Same journal

Mindfulness and meditation: Promoting emotional and cognitive health.

Progress in brain research·2025
Same journal

Cognitive stimulation enhancing memory and mental function.

Progress in brain research·2025
Same journal

The science behind non-pharmacological interventions.

Progress in brain research·2025
Same journal

Technology-assisted interventions for neuropsychiatric disorders.

Progress in brain research·2025
Same journal

Ethical consideration in non-pharmacological treatments for neuropsychiatric disorders.

Progress in brain research·2025
See all related articles

Pharmacological neuroprotection aims to reduce seizure damage by targeting initial insults or later cellular events. Improved preclinical tests are crucial for developing new neuroprotective and antiepileptogenic compounds, especially for childhood epilepsies.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Seizures can cause significant brain damage through initial insults and subsequent cellular events.
  • Pharmacological neuroprotection strategies target either the acute seizure activity (primary) or the downstream consequences (secondary).

Purpose of the Study:

  • To differentiate between primary and secondary neuroprotection mechanisms in seizure management.
  • To highlight the need for improved preclinical models for identifying novel neuroprotective and antiepileptogenic agents.
  • To identify opportunities for testing neuroprotective compounds in severe childhood epilepsies.

Main Methods:

  • Review of pharmacological targets for primary neuroprotection, including ion channels (Na+, Ca2+) and glutamate receptors (NMDA, AMPA/KA).

Related Experiment Videos

  • Analysis of secondary neuroprotection pathways targeting necrosis (free radical scavengers, NOS inhibitors, COX-2 inhibitors) and apoptosis (MAP-kinase, caspase-3 inhibitors).
  • Consideration of neurotrophin-related therapies for long-term morphological and functional effects.

    • Main Results:

    • Primary neuroprotection involves suppressing seizure activity and managing ionic fluxes.
    • Secondary neuroprotection targets cellular cascades (necrosis, apoptosis) or long-term effects following seizures.
    • Current preclinical tests require enhancement for effective identification of novel compounds.

    Conclusions:

    • Developing effective neuroprotective and antiepileptogenic therapies requires a deeper understanding of both primary and secondary mechanisms.
    • Severe childhood epilepsies offer a critical window for testing novel neuroprotective agents.
    • Improved preclinical models are essential for advancing the field of neuroprotection in epilepsy.